Deep Functional Phenotyping of the ALA Lung Health Cohort

Inclusion Criteria:

• Age 25-35 years at the time of the baseline examination

• Able to read and understand English or Spanish

• Has a social security number

• Resident (citizen or non-citizen) of the United States (US) for at least 12 monthsprior to examination.

Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.

• Willing to provide contact information for at least 2 proxies who are likely to knowthe whereabouts and vital status of the participant

Exclusion Criteria:

1. Severe asthma, which is defined as any of the following:

• Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA)Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting betaagonist (ICS/LABA) or high dose inhaled corticosteroid [ICS] or add-onlong-acting muscarinic antagonist (LAMA); Medium dose = >250 fluticasone,propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220mometasone). The investigators will accept low-dose ICS/LABA or medium doseICS. OR

• 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma inthe past 12 months OR

• One asthma hospitalization in the past 12 months

2. History of any chronic lung disease other than asthma including but not limited tochronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis,pulmonary hypertension

3. Current pregnancy

4. History of cancer other than non-melanoma skin cancer

5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heartdisease)

6. Inability to comply with study procedures, including

• Inability or unwillingness to provide informed consent

• Inability to perform study measurements

• Inability to be contacted by phone (via calls and/or text messaging) or email

7. Any condition in the opinion of the physician that puts the participant at risk byparticipating in the study (e.g., serious respiratory illness requiring antibioticsor steroids or severe fever at the time of the study visit).

8. Institutionalization